Loading…
← CockpitCompetitor Analysis › GUD.TO Knight Therapeutics, Inc.Open in the cockpit ↗

Knight Therapeutics, Inc.GUD.TOCompetitor analysis, valuation and peers

Canada · CAD·Health Care›Pharmaceuticals: Major
Momentum leader 96
Mkt cap
$792M
US dollars, full cap
Free float
77%
of shares outstanding
$/day
$564,207
20-day average traded
Fwd P/E
42.2×
forward earnings
ROIC−WACC
-1.9 pp
WACC 5.3%
Hurdle
-11 pp
Req g minus delivered
Next earnings
127 days
25 Mar 2027
Close · CADC$11.56
1D-1.4%
1W-3.9%
1M+1.0%
3M+17.7%
6M+41.3%
YTD+91.1%
1Y+88.6%
ATR %2.6%
52w lowhigh5.1% off high

What Knight Therapeutics does

Employees: 830

Knight Therapeutics at a glance

Size Knight Therapeutics (GUD.TO) is a Canada Health Care company (Pharmaceuticals: Major) with a market value of $792M, the 259th largest of 405 Canada companies the cockpit tracks. Shares closed at C$11.56 on 18 Nov 2026.

Performance Over six months the shares gained 41.3%, against -7.5% for the median peer and +1.1% for the Canada market (cap-weighted) — 3rd highest of 19 in its peer set.

Growth Revenue grew 36.1% over the last twelve months (peer median +2.1%); the operating margin is 5.5% (peer median 11.2%).

Valuation It trades at 42.2× forward earnings against a peer median of 10.8× (2nd most expensive of 8).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.9 points below its cost of capital (5.3% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026GUD.TO 139Peer median 93
Six months, rebased to 100: Knight Therapeutics against the median of its 20 peers (local-currency closes).

Knight Therapeutics financials

Reported figures in CAD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueC$563MC$450MC$371MC$328MC$294M
Revenue growth—+21%+13%+12%—
Gross profitC$215MC$151MC$130MC$108MC$86.3M
EBITDAC$93.7MC$54.4MC$60.6MC$56.8MC$46.0M
Net incomeC$16.0M-C$5.37MC$4.33M-C$16.8M-C$29.9M
Free cash flowC$127MC$68.4MC$40.9MC$27.5MC$41.6M
Capital expenditureC$16.2MC$33.7MC$31.5MC$9.96MC$25.8M
Total debtC$33.5MC$77.9MC$49.5MC$69.1MC$77.7M

Quarterly statements and history in the cockpit →

Knight Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%IRWDORICSANOFI002349ARDXRIGL688073000411SUVENCOLLBLISSGVS60783001002082603229GUD.TO6-month return →1-month return →
Up and to the right = strong over both horizons. Knight Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×100×200×IRWDSANOFIARDXRIGL688073COLL6078GUD.TORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Knight Therapeutics is the large dot.

Capital: growth delivered against growth the price implies

-40%-20%0%+20%-25%0%25%SANOFI002349RIGL688073COLLBLISSGVS60780023903001002082GUD.TOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Knight Therapeutics is the large dot.

Knight Therapeutics competitors and peer comparison

How Knight Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Knight Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureGUD.TOPeer medianRank in peer set
1-month return+1.0%-2.9%9th highest of 19
6-month return+41.3%-7.5%3rd highest of 19
Distance from 52-week high-5.1%-32.8%highest of 19
Revenue growth (TTM)+36.1%+2.1%2nd highest of 19
Operating margin5.5%11.2%9th lowest of 19
Forward P/E42.2×10.8×2nd most expensive of 8
Growth the price implies (Req g, 7 yrs)6.6%3.0%5th most demanding of 11
Growth delivered (Del g)+17.7%+6.4%5th highest of 11
Hurdle (Req g minus delivered)-11.1 pp-4.1 pp5th least demanding of 11
ROIC minus cost of capital-1.9 pp-0.5 pp9th lowest of 18
EV / EBITDA11.0×8.9×3rd most expensive of 8
Net debt / EBITDA-1.1×-0.1×3rd least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%42.2×6.6%+17.7%
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%3.5×n/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%19.6×16.3%-8.7%
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%n/a-2.5%+2.6%
Ardelyx ARDXUnited States$784M-50%+18%-8%252.9×n/an/a
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%10.8×1.5%+22.1%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%24.3×13.9%+27.7%
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%n/an/an/a
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%n/an/an/a
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%3.7×-2.6%+20.3%
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%n/a33.9%+10.1%
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%10.4×4.6%+22.5%
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%n/a-3.8%-0.8%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%n/an/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%n/a0.3%+0.5%
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%n/a27.7%-39.5%
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%n/an/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%n/an/an/a

Questions

Which companies are Knight Therapeutics's closest peers?
The cockpit's peer set: Ironwood Pharmaceuticals (IRWD), Bambusa Therapeutics (BBTX), Oric Pharmaceuticals (ORIC), Sanofi India (SANOFI.NS), Jinghua Pharmaceutical (002349.SZ), Ardelyx (ARDX), Rigel Pharmaceuticals (RIGL), Bide Pharmatech (688073.SS).
Is Knight Therapeutics expensive compared with its peers?
On forward p/e it trades at 42.2× against a peer median of 10.8×, 2nd most expensive of 8 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has Knight Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +41.3% against -7.5% for the median peer; over one year +88.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.